

Supplementary Table 2: CD4, CD19 cell count and humoral and cellular anti-SARS CoV2 response in patients in anti-CD20 treated patients: 26, 47 and 49 patients had a treatment interval between last anti-CD20 dose and vaccination of <6, <12 and >12 months, respectively. Fraction of patients, who fulfilled the CD4 cutoff (>653/ul) or CD19 cutoff (>27/ul) and the study visit and fraction of patients who with anti-SARS-CoV2 S1 above a threshold of 1.1 (Index s/c) and interferon-gamma release above 0.15 IU/ml.

	time since last anti-CD20		
	<6 months	<12 months	>12 months
	n = 26	n = 47	n = 49
CD4 cells > 653/ul	11/22 (50%)	18/41 (44%)	22/39 (56%)
CD19 cells > 27/ul	2/22 (9.1%)	8/41 (20%)	24/39 (62%)
anti-SARS-CoV2 S1 positive	5/26 (19%)	17/47 (36%)	30/49 (61%)
INFγ release positive	3/16 (19%)	6/31 (19%)	7/35 (20%)